Navigation Links
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Date:5/9/2013

LAWRENCEVILLE, N.J., May 9, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the first quarter ended March 31, 2013 and provided a business update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer.  ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer, The DIGNITY Study.

Following the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the HEAT Study's primary endpoint, the Company conducted a comprehensive analysis of the data from the Study which was reviewed by its key principal investigators as well as liver cancer and clinical data experts.  These emerging findings from the HEAT Study suggest that RFA dwell time had a positive impact on progression free survival (PFS) and overall survival (OS) in patients treated with ThermoDox® plus RFA when compared to the control group.  This analysis was conducted in a sizable patient subgroup.  These findings will be discussed by two of the HEAT Study's lead investigators at scientific sessions of the World Conference on Interventional Oncology on May 16, 2013. Celsion's lead investigators agree that these are interesting findings which should be further pursued.

"With the support of our medical advisors, we have been working diligently to better understand the clinical data and findings from the Phase III HEAT Study.  Concurrently, we have been taking appropriate measures to position C
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
2. Celsion Corporation Provides Business Update
3. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
4. Celsion Corporation Announces $15 Million Registered Direct Offering
5. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Verenium Corporation to Announce First Quarter 2013 Financial Results
8. EMCO High Voltage Corporation to Exhibit at 61st ASMS Conference on Mass Spectrometry and Allied Topics
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
11. Street Named After EMCO High Voltage Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... BETHESDA, Md., Sept. 16 Micromet, Inc. (Nasdaq: MITI ), ... inflammation and autoimmune diseases, today announced that its President and CEO, Dr. ... September 22, 2009 in New York City. A simultaneous webcast of ... , , ...
... ... RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential ... ... research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic ...
... , , CINCINNATI, Sept. 16 ... research organization, today announced the Company will participate in the upcoming ... Grand Hyatt New York Hotel in New York City. , ... , , Kendle,s formal presentation will be given ...
Cached Biology Technology:Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 2Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 3CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 2CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 3Kendle to Present at UBS Global Life Sciences Conference 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A new study that provides a snapshot of a ... of physical activity are strongly associated with being overweight or ... in fruits and vegetables did little to offset the effect ... who were mostly sedentary. Instead, exercise seemed to be the ...
... March 24 An experimental vaccine against an abnormal protein ... onset of inflammatory bowel disease (IBD) and in turn prevent ... of Pittsburgh School of Medicine. Their findings are reported this ... the American Association for Cancer Research. People with chronic ...
... A Worcester Polytechnic Institute (WPI) research team has ... Institutes of Health (NIH) to continue a groundbreaking study ... that will enable physicians to predict the likelihood of ... and strokes. Led by Dalin Tang, PhD, professor of ...
Cached Biology News:Rochester study connects workplace turmoil, stress and obesity 2Rochester study connects workplace turmoil, stress and obesity 3Rochester study connects workplace turmoil, stress and obesity 4Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 3
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
The filter 530DF28 for the Molecular Imager FX is a band pass filter for ECL Plus, AttoPhos, SYBR Green, Alexa Fluor 488, FITC, Cy2, and Pro-Q Emerald dyes....
... Sytem is a highly advanced digital ... digital imaging and automation technology that ... analysis, archving/retrieval and colored professional reporting. ... imaging system that aids in performing ...
... APO-DIRECT is a single-step staining method ... cells by flow cytometry. The kit contains ... apoptosis in cells including: positive and negative ... reaction and rinsing buffers for processing individual ...
Biology Products: